The study, presented at the 15th International Headache Congress in Berlin, tested St. Jude Medical’s Genesis neurostimulator.
At one year, 66 percent of patients reported excellent or good pain relief. Patients logged a 41 percent improvement on the Migraine Disability Assessment questionnaire, compared with a 13 percent improvement in a placebo group.
Read the St. Jude Medical release on peripheral nerve stimulation.
Related Articles on Neurostimulation:
Medtronic, St. Jude Developing Competing Neurostimulation Systems
SPR Therapeutics Nabs $250K Investment for Pain Relief Device
Study: Nerve Blockade Reduces Acute Pain After Hip Fracture
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
